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The qualitative Roche HIV-1 DNA Amplicor assay has been used for the past 20 years to diagnose HIV infection in infants and
young children but is being phased out; hence, alternative assays must be found. The Gen-Probe Aptima qualitative HIV-1 RNA
assay is currently the only FDA-cleared HIV-1 nucleic acid assay approved for diagnosis, but data on the use of this assay with
infant plasma are limited. We assessed Aptima’s performance using control material for reproducibility and limit of detection
and 394 plasma samples (0.2 to 0.5 ml) from HIV-exposed infected and uninfected infants and children for analytical sensitivity
and specificity. Assays to assess within-run repeatability and between-run reproducibility indicated that the controls with 10,000
(5 of 5), 200 (5 of 5), 100 (16 of 16), 50 (12 of 12), and 25 (20 of 20) HIV-1 RNA copies/ml (cp/ml) were always positive, and nega-
tives were always negative (20 of 20). The limit of detection was 14 cp/ml, as determined by probit analysis. The analytic sensitiv-
ity of the assay was 99.5% (189/190 samples; 95% confidence interval [CI], 97.1 to 99.9%) and specificity was 99.5% (199/200
samples; 95% CI, 97.2 to 99.9%). These results suggest that the assay is suitable for early infant diagnosis of HIV-1.
The Joint United Nations Program on HIV/AIDS (UNAIDS)estimates that children less than 15 years of age accounted
for roughly 13% of new HIV infections in 2011 (1). Addition-
ally, a meta-analysis concluded that with no intervention,
about 35% of African HIV-infected children die before their
first birthday, and more than 50% die by the time they are 2
years old (2). However, data from the Children with HIV Early
Antiretroviral Therapy (CHER) trial demonstrated that early,
as opposed to delayed, initiation of antiretrovirals (ARVs) in
young infants significantly reduced mortality (3), and data
from several clinical trials have indicated that infected infants
exposed to prophylactic ARVs often develop resistance to the
drugs, which may limit future therapeutic drug choices (4–6).
Thus, early identification of HIV infection in infants is impor-
tant so that ARV prophylaxis can be stopped to reduce the
development of resistance to the ARVs, and therapeutic doses
of ARVs can be initiated as quickly as possible. Early diagnosis
of HIV infection using serologic testing of antibodies, however,
is hindered by the presence of maternal antibodies that cross
the placenta during gestation. Consequently, early infant diag-
nostics must test for either viral antigens or nucleic acids.
For many years, the Roche Amplicor HIV-1 DNA assay, ver-
sion 1.5, has been the mainstay and gold standard for early infant
diagnosis (EID), having been validated and used extensively in
many countries and recommended by the World Health Organi-
zation, as well as the U.S. Centers for Disease Control and Preven-
tion, for EID programs using both whole-blood pellets and dried
blood spots (DBS) (7). However, Roche plans to discontinue this
assay in the next few years, so alternative assays must be found (8).
Although there are several alternatives, including the Roche
TaqMan and Abbott RealTime quantitative HIV-1 RNA and qual-
itative HIV-1 total nucleic acid assays, the Gen-Probe Aptima
HIV-1 RNA qualitative assay is the only nucleic acid assay cur-
rently approved by the FDA for HIV diagnosis using serum or
plasma (9). Although its utility in EID using DBS (10–12) and
whole blood (11) has been reported, data on the use of this assay
using infant plasma are limited. The New York State Department
of Health evaluated Aptima for infant diagnosis but tested only
plasma from 28 HIV-exposed uninfected babies and 68 HIV-in-
fected infants (T. J. Sullivan, T. T. Miller, B. Warren, M. M. Parker,
presented at the Third HIV Diagnostics Conference, Orlando, FL,
24 to 26 March 2010). An additional 48 sera from HIV-exposed,
uninfected infants were tested and found to be nonreactive in the
Aptima assay (13).
MATERIALS AND METHODS
Samples. The limit of detection, within-run repeatability, and between-
run reproducibility were assessed using control material obtained from
the Virus Quality Assurance Program (VQA; Rush University Medical
Center, Chicago, IL) (14) diluted in Basematrix (SeraCare, Milford, MA).
Repeatability was assessed by diluting the VQA HIV-1 RNA 200-copy/ml
(cp/ml) control material to final concentrations of 100 and 25 HIV-1 RNA
cp/ml and testing in duplicate in 4 separate runs by two technologists.
Reproducibility was determined by testing three positive VQA controls
(10,000, 200, and 50 cp/ml) and a negative control in singlet over 5 days
using 2 different kit lots. To assess the limit of detection, we made addi-
tional dilutions to 0.4 cp/ml that were tested in 4 separate runs by two
technologists using 3 kit lots. Fewer samples were tested at the highest
concentrations (n  5 to 8 replicates) than at lower concentrations, which
were tested more frequently (n  10 to 20 replicates). There were a few
invalid results that were not included in the analysis. Basematrix was used
as HIV RNA negative-control material for all these experiments.
Analytic sensitivity was assessed using 114 plasma samples ob-
tained from HIV-infected infants 3 to 12 months old (median, 7
months) and 79 plasma samples from older children (13 months to 18
years old; median, 9.3 years) who had been enrolled in Pediatric AIDS
Clinical Trials Group Study 152 (15). Specificity was evaluated using
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plasma samples from 201 HIV-exposed uninfected infants enrolled in
International Maternal Pediatric Adolescent AIDS Clinical Trials
Study P1025 (16). Infection status for these infants had been deter-
mined previously either by HIV culture (17) or HIV DNA PCR testing
(Roche Amplicor; Roche Molecular Systems, Branchburg, NJ) in lab-
oratories successfully participating in the VQA proficiency testing pro-
gram (17, 18). Testing personnel were blinded to the previously deter-
mined infection status of each specimen.
Assay. The Gen-Probe Aptima qualitative HIV RNA assay (Hologic
Gen-Probe, Inc., San Diego, CA) was performed by following the manu-
facturer’s package insert (9) using 0.5 ml of plasma, when available. In 42
cases, less than 0.5 ml was tested (0.4 ml, 19 times; 0.35 ml, 10 times; 0.3
ml, 8 times; 0.25 ml, 4 times; and 0.2 ml, once). Assay software was used to
compare the relative light units reported by a luminometer to run-specific
cutoffs.
Analysis. Analyses were conducted with Stata SE, version 13.0. The
95% limit of detection was assessed using probit analysis incorporating
the base 10 logarithm of the HIV-1 RNA cp/ml. Sensitivity and specificity
were calculated using standard methods, considering HIV culture and
HIV DNA PCR with Roche Amplicor as the reference standard. Ninety-
five-percent confidence intervals (95% CI) were calculated for sensitivity,
specificity, and repeatability using the Wilson method (19).
This research was approved by the chairs of Pediatric AIDS Clinical
Trials Group Study 152 and the International Maternal Pediatric Adoles-
cent AIDS Clinical Trials Study P1025, as well as by the Institutional
Review Board at the University of North Carolina at Chapel Hill (10-
0529).
RESULTS
Assays to assess within-run repeatability and between-run repro-
ducibility indicated that the controls of 10,000 (5 of 5), 200 (5 of
5), 100 (16 of 16), 50 (12 of 12), and 25 (20 of 20) HIV-1 RNA
cp/ml were always positive, and the negatives were always negative
(20 of 20) (Tables 1 and 2). Experiments to assess the limit of
detection indicated that the assay could detect 25 HIV RNA cp/ml
100% of the time and 6 to 12.5 cp/ml 75 to 90% of the time.
Detection dropped off sharply after that (Table 2). In probit anal-
ysis, the 95% limit of detection was 14.1 cp/ml.
Of the 394 clinical samples tested, only 4 were invalid (1.0%);
these were excluded from data analysis. Analytic sensitivity was
99.5% (189/190 samples; 95% CI, 97.1 to 99.9%) (Table 3), de-
spite limited sample volume for 42 infants. Specificity was 99.5%
(199/200 samples; 95% CI, 97.2 to 99.9%). Signal-to-cutoff (S/
CO) ratios for reactive samples ranged from 2.7 to 38.3, with
96% (182/189) of reactive samples with S/CO ratios greater than
19.0 (median S/CO ratio for all reactive specimens was 22.0).
There was no indication that specimens from infected babies
where less than 0.5 ml of plasma was used had lower S/CO ratios,
since 11.5% of specimens (17/148) with full volumes had S/CO
ratios of 20.0, compared to 11.9% of specimens (5/42) with
0.5 ml. The single false negative had an S/CO ratio of 0.30. The
single false-positive result had an S/CO ratio of only 2.68 and
would have been repeated under the laboratory’s standard oper-
ating procedures had there been sufficient plasma. Signal-to-cut-
off ratios for nonreactive specimens ranged from 0.06 to 0.55, with
90% (181/200 samples) 0.20.
DISCUSSION
The Aptima assay appears extremely sensitive, with a limit of de-
tection of 14.1 cp/ml. Kerr et al. (10) found that DBS from 5 of 8
adults with HIV RNAs 50 cp/ml were detected in the Aptima
assay. Similarly, Stevens et al. (11) performed dilution experi-
ments with DBS and found that the Aptima assay generated reac-
tive results that were 1 to 3 log units more sensitive than the Roche
Amplicor assay. Lilian et al. reported that at birth, 2 weeks, and 4
weeks, Aptima detected 76%, 64%, and 96%, respectively, of in-
fected children compared to 68%, 64%, and 88% by the Roche
Amplicor assay using DBS (12). Furthermore, Aptima detected
HIV infection in the sera of 6 children an average of 28 days earlier
(range, 18 to 65 days) than HIV DNA testing (T. J. Sullivan, T. T.
Miller, B. Warren, M. M. Parker, presented at the Third HIV
Diagnostics Conference, Orlando, FL, 24 to 26 March 2010). This
increased sensitivity may be important, as more infants are ex-
posed to combination ARVs for prevention of mother-to-child
transmission (20, 21).
Previous work in our laboratory suggested that S/CO ratios
between 1.0 and 5.0 were suspect and should be repeated (unpub-
lished observations). Only three of the 394 clinical specimens had
S/CO ratios that fell in this range (2.68, 4.08, and 4.17), and none
of these had sufficient volume to repeat. Stevens et al. (11) also
reported improved specificity when DBS with S/CO ratios less
than 10 were repeated. Analytic specificity in HIV-exposed, unin-
fected children 18 months of age has been consistently high,
ranging from 99.4 to 100% (10–12).
A major limitation of this study was that none of the specimens
TABLE 1 Within-run and between-run repeatability of the Aptima
HIV-1 RNA assay
Repeatability
Concn (cp/ml) of control
HIV-1 RNA
No. of reactive samples/
no. of tested samples
(%; 95% CI)
Within run 100 8/8 (100; 67.6–100)
25 8/8 (100; 67.6–100)
Basematrix negative control 8/8 (100; 67.6–100)
Between run 10,000 5/5 (100; 56.6–100)
200 5/5 (100; 56.6–100)
50 5/5 (100; 56.6–100)
TABLE 2 Limit of detection of the Aptima HIV-1 RNA qualitative assay
Concn (cp/ml) of control
HIV-1 RNA
No. of reactive samples/no. of
tested samples (%; 95% CI)
100 8/8 (100; 67.5–100)
50 7/7 (100; 64.6–100)
25 12/12 (100; 75.8–100)
12.5 11/12 (91.6; 64.6–98.5)
6.1 9/12 (75; 46.8–91.1)
3.1 5/10 (50; 23.7–76.3)
1.6 5/10 (50; 23.7–76.3)
1 0/12 (0; 0, 24.2)
Negative control 0/12 (0; 0, 24.2)
TABLE 3 Sensitivity and specificity of the Aptima HIV RNA qualitative
assay
Aptima result
No. of samples with a culture or DNA
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from infected children were obtained before the first 6 weeks of
life, when sensitivity for HIV diagnosis is typically low (22). With
increased uptake of more potent ARVs for the prevention of
mother-to-child transmission, the proportion of intrauterine
transmission compared to intrapartum transmission has in-
creased, and thus more infected babies are detected at birth rather
than at 6 weeks (23). Another limitation is that the infected infants
had minimal exposure to ARVs and then only to zidovudine and
not to combination prophylaxis ARVs that are commonly in use
today (20, 21). Some have argued that detection of HIV DNA or
total nucleic acid may be more sensitive than HIV RNA detection
when infants are exposed to prophylactic or therapeutic levels of
ARVs (20, 21), although a recent study does not confirm that
hypothesis (24).
A further limitation is that, in most cases, the recommended
500 l of plasma was tested, but it is often difficult to obtain a full
500 l of plasma from newborn infants. Our limited data on sam-
ples with less than the full 0.5 ml of plasma and the exquisite
sensitivity of the assay (14 cp/ml limit of detection) suggest that
smaller volumes of plasma could be used if appropriately vali-
dated. We did not have access to fresh whole blood from infected
infants since perinatal HIV infection is now rare in North Carolina
(S. Fiscus, unpublished data). In addition, the Aptima package
insert states that whole blood should not be frozen prior to testing.
However, Stevens et al. (11) diluted whole blood in reverse osmo-
sis water prior to transport to the laboratory, where it was appar-
ently immediately loaded onto the Tigris instrument for analysis.
This option would be feasible only in a high-throughput labora-
tory.
Since sufficient volumes of whole blood and plasma may be
difficult to obtain, especially in neonates, DBS may offer an attrac-
tive alternative. Our previous data (10) and those of others (11,
12) demonstrate that DBS yield extremely sensitive and specific
results and have been recommended for use in low-resource
countries with other HIV-1 nucleic acid assays as a means to pro-
vide greater accessibility to testing (7, 8, 25). The Aptima assay is
currently being used in New York State to identify HIV infection
in infants (26) and should be considered an alternative to the
Roche Amplicor HIV-1 DNA assay for infant diagnosis.
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